ARQ 197

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Hepatocellular Carcinoma

Conditions

Advanced Hepatocellular Carcinoma

Trial Timeline

Jul 1, 2012 → Mar 1, 2014

About ARQ 197

ARQ 197 is a phase 1 stage product being developed by Kyowa Kirin for Advanced Hepatocellular Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01656265. Target conditions include Advanced Hepatocellular Carcinoma.

What happened to similar drugs?

16 of 20 similar drugs in Advanced Hepatocellular Carcinoma were approved

Approved (16) Terminated (1) Active (4)
ApatinibTabletsJiangsu Hengrui MedicineApproved
letrozoleJiangsu Hengrui MedicineApproved
FulvestrantAstraZenecaApproved
Zoladex and CasodexAstraZenecaApproved
GefitinibAstraZenecaApproved
Alpelisib + FulvestrantNovartisApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01656265Phase 1Completed
NCT01580735Phase 2Completed
NCT01152645Phase 2Completed

Competing Products

20 competing products in Advanced Hepatocellular Carcinoma

See all competitors
ProductCompanyStageHype Score
mRNA-4359ModernaPhase 2
0
mRNA-4106ModernaPhase 1
0
AK-105AkesoPhase 1
29
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
14
EXS21546BiotrialPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
NBTXR3NanobiotixPhase 1/2
33
pegfilgrastim + LY2523355Eli LillyPhase 1
29
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
BT1718Bicycle TherapeuticsPhase 1/2
22
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
IMC-18F1Eli LillyPhase 1
29
Tadalafil + GemcitabineEli LillyPhase 1
29
OKI-179OnKure TherapeuticsPhase 1
19
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
26
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
24
LY3434172Eli LillyPhase 1
21